<DOC>
	<DOC>NCT01737866</DOC>
	<brief_summary>A phase 1, open-label study in subjects with normal renal function and subjects with various degrees of renal insufficiency, including patients with end-stage renal disease (ESRD) requiring hemodialysis. The primary objective is to evaluate the single-dose PK of AMG 423 in subjects with various degrees of renal insufficiency, including patients with end-stage renal disease requiring hemodialysis.</brief_summary>
	<brief_title>Pharmacokinetics Study of AMG 423 in Healthy Subjects and Subjects With Various Degrees of Renal Insufficiency</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<criteria>Men or women â‰¥18 years of age Laboratory test values (clinical chemistry and hematology)within normal limits, (other than test values out of the normal range for subjects with CKD [groups 1 and 3 through 5]), or clinically acceptable to the investigator and sponsor at screening and day 3 Free of any clinically significant disease or condition(s) (other than that consistent with CKD for subjects in groups 1 and 3 through 5) that require a physician's care and/or would interfere with the evaluations, procedures, or participation in the study per the investigator's discretion; Subjects whose second MDRD eGFR result during the screening period is not within 10% of the first eGFR result Subjects who have received a functioning renal transplant within the past year Subjects with ESRD who do not have a functioning hemodialysis access Subjects with hemodynamic instability during hemodialysis Subjects whose renal insufficiency is due to active autoimmune renal disease Subjects with renal insufficiency or ESRD requiring hemodialysis and Troponin I &gt; upper limit of normal (ULN) at screening or day 3 Subjects with history of heart disease or unstable angina within the last 3 months Subjects with uncontrolled diabetes (Hb1Ac &gt; 8%) and/or subjects who are able but unwilling to adhere to the required fasting intervals</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Heart, Failure, Renal, Insufficiency, Cardiac, Kidney, Hemodialysis, Impairment, omecamtiv mecarbil, cardiac myosin activator, CK-1827452</keyword>
</DOC>